Find Funding Opportunities

Notice Extension the Expiration Date PA-11-345 NeuroNEXT Small Business Innovation Clinical Trials U44)" Notice Number: NOT-NS-14-012 Key Dates Release Date: March 12, 2014 Related Announcements PAR-11-345 Issued National Institute Neurological Disorders Stroke NINDS)  Purpose Notice extends expiration date PAR-11-345, quot;NeuroNEXT Small Business Innovation Clinical Trials U44)" one receipt date. Due the extension, following application due date be added, December 2, 2014. Current Expiration Date: August 2, 2014. New Expiration Date: December 3, 2014. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Amanda Sibley, DPhil, MPH National Institute Neurological Disorders Stroke NINDS) Phone: 301-451-1449 Email: amanda.sibley@nih.gov nbsp;

Notice the Transition New Application Forms NeuroNEXT Infrastructure Resource Access X01)” Notice Number: NOT-NS-14-015 Key Dates Release Date: March 7, 2014 Related Announcements PAR-11-344 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform applicants new application forms now available Funding Opportunity Announcement FOA) PAR-11-344 ldquo;NeuroNEXT Infrastructure Resource Access X01)”. new application forms be identified the Grants.gov Download Application Package screen the Competition ID lsquo;FORMS-C’. older application forms a Competition ID lsquo;ADOBE-FORMS-B1’. Although FORMS-C application forms available immediate use, National Institute Neurological Disorders Stroke NINDS) allow transition period through March 28, 2014 during time applications using ADOBE-FORMS-B1 forms still accepted. application submissions PAR-11-344 on after March 29, 2014 must FORMS-C application forms NOT-OD-13-074). other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: D. Elizabeth McNeil, MD MSc National Institute Neurological Disorders amp; Stroke NINDS) Telephone: 301-496-9135 Email: mcneilde@ninds.nih.gov nbsp;

Notice Extend Due Date Expiration Date RFA-MH-14-217 BRAIN Initiative: Planning Next Generation Human Brain Imaging R24)" Notice Number: NOT-MH-14-010 Key Dates Release Date: March 5, 2014 Related Announcements RFA-MH-14-217 Issued NIH Blueprint Neuroscience Research http://neuroscienceblueprint.nih.gov) National Eye Institute NEI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) National Institute Biomedical Imaging Bioengineering NIBIB) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Deafness Other Communication Disorders NIDCD) National Institute Dental Craniofacial Research NIDCR) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute General Medical Sciences NIGMS) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) National Institute Nursing Research NINR) National Center Complementary Alternative Medicine NCCAM) National Center Advancing Translational Sciences NCATS) Office Behavioral Social Sciences Research OBSSR) Purpose purpose this Notice to inform interested applicants the Application Due Date RFA-MH-14-217 quot;BRAIN Initiative:  Planning Next Generation Human Brain Imaging R24)" being extended March 13, 2014, March 27, 2014. Accordingly, expiration date RFA-MH-14-217 now March 28, 2014. other aspects the FOA remain unchanged. Inquiries Please direct inquiries to: Greg Farber, Ph.D. National Institute Mental Health NIMH) Telephone: 301-435-0778 Email: faberg@mail.nih.gov nbsp;

Notice Correct NINDS CFDA Number Associated PAR-13-278 NINDS Phase III Investigator-Initiated Efficacy Clinical Trials U01)" Notice Number: NOT-NS-14-017 Key Dates Release Date: March 4, 2014 Related Announcements PAR-13-278 NOT-NS-14-008 Issued National Institute Neurological Disorders Stroke NINDS) Purpose January 16, 2014 National Institute Neurological Disorders Stroke NINDS) issued Notice NOT-NS-14-008) informing applicants the CFDA number for  PAR-13-278 quot;NINDS Phase III Investigator-Initiated Efficacy Clinical Trials U01)" should 93.853. Unfortunately, application packages available Grants.gov still reflected old CFDA number. Although is standard practice NIH staff verify correct CFDA numbers after submission, applicants raised concerns regarding display the incorrect CFDA their applications. address concerns, have posted new application package Grants.gov identified a Competition ID lsquo;FORMS-C-REVISED’ a Competition Title lsquo;Includes CFDA correction – must used due dates or after 8, 2014'. you already started prepare application the March 5, 2014 due date renewal, resubmission revision applications the 7, 2014 due date AIDS AIDS-Related applications, you two options: 1. Submit using old application package. Although application image eRA Commons show old CFDA, NIH staff adjust CFDA number our system process application correctly. 2. Revisit PAR-13-278, download new application package, transfer application data submission. After May 7, 2014 AIDS due date, old application package be closed application submissions using old package no longer accepted. Inquiries Please direct inquiries to: Wendy Galpern, MD, PhD National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-9135 Email: Phase3Trial@ninds.nih.gov

Notice Correct NINDS CFDA number associated PAR-13-281 NINDS Exploratory Clinical Trials R01)" Notice Number: NOT-NS-14-016 Key Dates Release Date: March 3, 2014 Related Announcements PAR-13-281 NOT-NS-14-007 Issued National Institute Neurological Disorders Stroke NINDS) Purpose January 16, 2014 National Institute Neurological Disorders Stroke NINDS) issued Notice NOT-NS-14-007) informing applicants the CFDA number PAR-13-281 quot;NINDS Exploratory Clinical Trials R01)" should 93.853. Unfortunately, application packages available Grants.gov still reflected old CFDA number. Although is standard practice NIH staff verify correct CFDA numbers after submission, applicants raised concerns regarding display the incorrect CFDA their applications. address concerns, have posted new application package Grants.gov identified a Competition ID lsquo;FORMS-C-REVISED’ a Competition Title lsquo;Includes CFDA correction – must used due dates or after 8, 2014'. you already started prepare application the March 5, 2014 due date renewal, resubmission revision applications the 7, 2014 due date AIDs AIDS-Related applications, you two options: 1. Submit using old application package. Although application image eRA Commons show old CFDA, NIH staff adjust CFDA number our system process application correctly. 2. Revisit PAR-13-281, download new application package, transfer application data submission. After May 7, 2014 AIDS due date, old application package be closed application submissions using old package no longer accepted. Inquiries Please direct inquiries to: Peter R. Gilbert, Sc.M. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-0870 Email: ExploratoryTrial@ninds.nih.gov

Notice NINDS Participation PAR-14-092 Bioengineering Research Partnerships BRP) R01)" Notice Number: NOT-NS-14-014 Key Dates Release Date: March 3, 2014 Related Announcements PAR-14-092 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this Notice to inform applicants the National Institute Neurological Disorders Stroke NINDS) joined funding opportunity announcement PAR-14-092, entitled ldquo;Bioengineering Research Partnerships BRP) R01)”, effective immediately. following sections PAR-14-092 been updated reflect participation NINDS this FOA. Part 1. Overview Information Components Participating Organizations National Institute Biomedical Imaging Bioengineering NIBIB) National Cancer Institute NCI) National Eye Institute NEI) National Human Genome Research Institute NHGRI) National Institute Aging NIA) National Institute Alcohol Abuse Alcoholism NIAAA) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Drug Abuse NIDA) National Institute Environmental Health Sciences NIEHS) National Institute Neurological Disorders Stroke NINDS) Catalog Federal Domestic Assistance CFDA) Number(s) 93.286, 93.172, 93.865, 93.399, 93.396, 93.395, 93.394, 93.393, 93.273, 93.867, 93.279, 93.113, 93.866, 93.853 Part 2. Section I. Funding Opportunity Description  Scope the Program applications relevant the mission the National Institute Neurological Disorders Stroke NINDS): NINDS not support first human demonstrations, early Feasibility studies definitive clinical trials therapeutics through BRP mechanism Phase I, Phase II, Phase III, Feasibility/Pivotal trials), does support efforts through mechanisms http://www.ninds.nih.gov/research/clinical_research/ details).  Pre-clinical efforts leading directly an FDA submission obtain Investigational Device Exemption IDE) also supported through mechanisms http://www.ninds.nih.gov/funding/funding_announcements/Funding-Bins-Tra… details).  Investigators should contact NINDS Program Staff identify appropriate mechanism such clinical efforts. other aspects this FOA remain unchanged. Inquiries Please direct inquiries to: Kip Ludwig, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1447 Email: Kip.Ludwig@nih.gov

Discontinuation PAR-13-022 NINDS Cooperative Program Translational Research U01)" Notice Number: NOT-NS-14-013 Key Dates Release Date: February 13, 2014 Related Announcements PAR-13-022 Issued National Institute Neurological Disorders Stroke NINDS) Purpose Notice to inform potential applicants NINDS discontinue PAR-13-022 quot;NINDS Cooperative Program Translational Research U01)." Applications not accepted NINDS this Funding Opportunity Announcement after February 7, 2014 application due date.  Notices announcing related new programs be forthcoming. Inquiries Please direct inquiries to: Linda McGavern, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1779 Email: CREATEinquiries@mail.nih.gov nbsp;

Request Information RFI): Areas Research Aimed a Cure Lifelong Remission HIV Infection Notice Number: NOT-AI-14-034 Update: following update relating this announcement been issued: February 21, 2014 - Notice NOT-AA-14-002. Notice NIAAA Participation. Key Dates Release Date: February 5, 2014 Response Date: March 14, 2014 Related Announcements None Issued National Institute Allergy Infectious Diseases NIAID) National Institute Alcohol Abuse Alcoholism NIAAA) National Cancer Institute NCI) Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) National Institute Drug Abuse NIDA) National Institute Mental Health NIMH) National Institute Neurological Disorders Stroke NINDS) NIH Office AIDS Research OAR) Purpose Commemorating World AIDS Day December 2, 2013, President Obama announced redirection 100 million expand support research aimed a cure lifelong remission HIV infection purpose this Request Information RFI) to seek input the scientific community regarding high priority research areas related HIV persistence the development strategies eradicating controlling virus remaining despite optimal antiretroviral treatment. information obtained responses aid NIH prioritizing areas be supported HIV cure-related research. Background HIV infection a disease is manageable lifelong effective antiretroviral therapy; however cure remains elusive. Despite prolonged suppression viral replication very low levels, antiretroviral therapy discontinued, viral replication rebounds pretreatment levels nearly infected persons. report a single case a cure an adult underwent stem cell transplants well the report an infant was cured HIV infection early treatment initiated the second day life renewed interest the field cure-related research highlighted need further basic research understand sources and reservoirs residual viremia, mechanisms facilitate persistence,  better assays evaluating measuring persistent HIV well evaluation therapeutic concepts targeting residual virus. Currently, broad program cure-related research supported across NIH.  research spans Institutes addresses range issues, including basic science, adult pediatric research, neuroAIDS. funds available through President’s directive offers NIH opportunity expand research opportunities. Input the research community important identify those research areas highest priority warrant additional support. Information Requested RFI invites scientific community provide comments can include are limited the following areas: 1. a) HIV cure-related research topics should considered high priority.    b) new basic information, technologies, resources are needed facilitate progress this area.    2. a) Areas cure-related research, any, should considered lower priority.   b) approaches have already been, are currently being, explored a sufficient level. 3. a) balance point between basic, translational clinical evaluations would provide optimal mix rapidly advance cure research.    b) type expertise should included enhance better enable research toward cure. c) new initiatives are needed on topics should focus.    d) grant mechanisms would most appropriate.   4. a) Any existing initiatives cure-related programs should expanded abolished.    b) existing programs currently not include cure-related research could logically expanded include cure-related research part the scope. Responses Responses be accepted through March 14, 2014. Please respond email to: CureRFI@nih.gov include text RFI Reply” the subject line. Please specify area are providing responses to. Only submissions this email address be considered this RFI. Please limit total response a maximum 3 pages. interested extramural investigators other interested parties invited respond. Responders free address any all the above items.  individual responses remain confidential. Any identifiers e.g., names, institutions, email addresses, etc.) be removed responses compiled. Only processed, anonymized results be shared internally NIH staff members, appropriate. U.S. Government cannot guarantee confidentiality the information provided. Responders advised the U.S. Government under obligation acknowledge receipt the information received provide feedback responders respect any information submitted. RFI for information planning purposes only should be construed a solicitation applications as obligation the part the U.S. Government provide support any ideas identified response it.  U.S. Government not pay the preparation any information submitted for use that information. Responders should aware the information provided be analyzed may used develop future funding opportunity announcements and/or appear various reports. Inquiries Responses this RFI should only submitted the email address noted above Responses”.  Questions this RFI be directed any the NIH staff members listed below: Paul Sato, M.D. Office AIDS Research Telephone:   301-480-2330  Email:  paul.sato@nih.gov Diana Finzi, Ph.D. National Institute Allergy Infectious Diseases NIAID) Telephone:   301-451-2598 Email: dfinzi@niaid.nih.gov Sarah Read, M.D. National Institute Allergy Infectious Diseases NIAID) Telephone:   301-451-2757 Email: readsa@niaid.nih.gov Katherine Davenny, M.P.H. National Institute Drug Abuse NIDA) Telephone:   301-443-2146 Email: kdavenny@nida.nih.gov Rohan Hazra, M.D. Eunice Kennedy Shriver National Institute Child Health Human Development NICHD) Telephone:  301-435-6868 Email:  hazrar@mail.nih.gov Stephen Hughes, Ph.D. National Cancer Institute NCI) Telephone:  301-846-1619 E-mail: hughesst@mail.nih.gov Jeymohan Joseph, Ph.D. National Institute Mental Health NIMH) Telephone: 301-443-3012 Email: jjeymoha@mail.nih.gov Wong, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-1431 Email: wongm@ninds.nih.gov  

Notification a Change Funding Level NINDS Research Education Programs Residents Fellows Neurology, Neurosurgery, Neuropathology Neuroradiology R25) Notice Number: NOT-NS-14-010 Key Dates Release Date: January 30, 2014 Related Announcements RFA-NS-09-001 RFA-NS-10-002 NOT-NS-12-022 PAR-13-384 Issued National Institute Neurological Disorders Stroke NINDS) Purpose purpose this notice to inform those holding active grants were funded under of three Funding Opportunity Announcement FOAs) mentioned below that, effective immediately, administrative supplement support FY 2014 participants conform the budgetary allowances described participants PAR-13-384. NINDS issued three FOAs RFA-NS-09-001, RFA-NS-10-002, RFA-NS-12-003) encourage submission administrative supplements support residents fellows Neurology, Neurosurgery, Neuropathology Neuroradiology conduct research. these three FOAs, direct cost allowed each participating resident fellow limited 70,000. November 2013, NINDS published new FOA PAR-13-384) continuation this program. Because participant's salary fringe requirements exceed 70,000 direct cost maximum, new FOA omitted dollar amount cap direct cost support each individual participant. new FOA supports resident fellow salary fringe benefits to 80% the institution's PGY amount relevant that participant, commensurate the duration the participant's commitment the R25 program activities. addition, additional 3,000 per participant provided travel a scientific meeting an NINDS-sponsored workshop, up 10,000 per year provided per program year administrative costs. Inquiries Please direct inquiries to: Stephen Korn, Ph.D. National Institute Neurological Disorders Stroke NINDS) Telephone: 301-496-4188 Email: korns@ninds.nih.gov nbsp;

Request Information RFI): Input the European Multi-PART Multicenter Preclinical Animal Research Team) planning effort generate international preclinical stroke network infrastructure Notice Number: NOT-NS-14-006 Key Dates Release Date: January 16, 2014 Response Date: February 7, 2014 Related Announcements None Issued National Institute Neurological Disorders Stroke NINDS) Purpose National Institute Neurological Disorders Stroke NINDS) requesting opinions the US stroke research community regarding European Multi-PART Multicenter Preclinical Animal Research Team; www.multi-part.org) initiative.  Background Multi-PART a planning effort intended generate infrastructure an international preclinical stroke network. overall objective to develop capacity undertake international multicenter animal studies improve validity generalizability current preclinical research. consortium, group internationally recognized scientists broad comprehensive expertise, proposes perform preclinical studies the same rigor centralized coordination characterize multicenter Phase III randomized controlled clinical trials humans. Creating such network identified a cross-cutting priority the 2012 NINDS Stroke Research Priorities Meeting http://www.ninds.nih.gov/find_people/ninds/OSPP/Stroke-Research-Priorit…, a description the recommendations developed that conference). Request Information Investigators actively conducting stroke research encouraged provide brief description to exceed 2 pages) their view regarding benefits risks US stroke investigators participating Multi-PART, area(s) expertise stroke research, potential contribution the Multi-PART planning effort. to Submit Response Responses be accepted through February 7th, 2014. Electronic responses preferred may addressed Multi-Part-Volunteers@ninds.nih.gov please include Notice number, NOT-NS-14-006, the subject line). Responses also sent letter fax the following address: Francesca Bosetti, Pharm.D., Ph.D. Program Director, Neural Environment Cluster National Institute Neurological Disorders Stroke National Institutes Health 6001 Executive Blvd. Rm. 2115 Bethesda, MD 20892-9521 Fax: 301-402-2060 Responses this RFI voluntary, will reviewed NINDS. RFI for planning purposes only, is a solicitation applications an obligation the part the United States U.S.) Government provide support any ideas identified response it. Please note the U.S. Government not pay the preparation any comment submitted, for use that comment. Inquiries Please direct inquiries to: Francesca Bosetti, Pharm.D., Ph.D. National Institute Neurological Disorders Stroke NINDS) Phone: 301-496-1431 Email: frances@mail.nih.gov nbsp;